Summary of the First International Symposium on Viral Hepatitis

Antiviral Research

Volumn 42, Issue 2, 1999, Pages 77-96

  González Peralta, Regino P ^a   Galasso, George J ^b   Poynard, Thierry ^c   Schalm, Solko ^d   Thomas, Howard C ^e   Wright, Teresa L ^f  

^a Divisions of Gastroenterology   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ST MARY S HOSPITAL   (United Kingdom)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Animal models; Hepatitis; Hepatitis B; Hepatitis C; Hepatitis D; Therapy

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; DEXTRO DIAMINOPURINDIXOLANE; DIDEOXYFLUOROTHIACYTIDINE; FLUOROMETHYLARABINOSYLURACIL; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; MACROGOL; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBAVIRIN; TETRACYCLINE; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; CHIMPANZEE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DELTA AGENT HEPATITIS; DRUG RESEARCH; DUCK; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IMMUNITY; IMMUNOMODULATION; LIVER CELL DAMAGE; LIVER TRANSPLANTATION; MEDICAL RESEARCH; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS HEPATITIS; WOODCHUCK;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, ANIMAL; HEPATITIS, VIRAL, HUMAN; HUMANS;

ANAS SP.; ANIMALIA; DELTA VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; MARMOTA MONAX; PAN TROGLODYTES;

EID: 0344780821     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00023-6     Document Type: Conference Paper

References (89)

1. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
2. Atkins M., Hunt C.M., Brown N., Gray F., Sanathanan L., Woessner M., Lai C.L., Dusheiko G., Dienstag J., Wright T.L., Barnard J., Bourne E., Condreay L. Clinical-significance of YMDD mutant hepatitis-B virus (HBV) in a large cohort of lamivudine-treated hepatitis- B patients. Hepatology. 28:1998;625A.
3. Bartenschlager R., Ahlborn-Laake L., Mous J., Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67:1993;3835-3844.
4. Berenguer M., Ferrell L., Kim M., Prieto M., Rayon M., Garcia A., Watson J., Ascher N., Mir J., Berenguer J., Wright T.L. Fibrosis progression in recurrent HCV disease: differences between the US and Europe. Hepatology. 28:1998;230S.
5. Bodenheimer H.C., Lindsay K.L., Davis G.L., Lewis J.H., Thung S.N., Seeff L.B. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 26:1997;473-477.
6. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., Scognamiglio P., Boehme R., Panebianco R., Fiaccadori F., Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:1998;968-975.
7. Botarelli P., Brunetto M.R., Minutello M.A., Calvo P., Unutmaz D., Weiner A.J., Choo Q.L. et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 194:1993;80-587.
8. Bradley D.W., McCaustland K.A., Cook E.H., Schable C.A., Ebert J.W., Maynard J.E. Posttransfusion non-A, non-B hepatitis in chimpanzees: physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology. 88:1985;773-779.
9. Branch A.D., Robertson H.D. A replication cycle for viriods and other small infectious RNAs. Science. 223:1984;450-455.
10. Brillanti S., Garsoin J., Foli M., Whitby K., Deaville R., Masci C., Miglioli M. et al. A pilot study combination therapy with ribavirin and interferon α for and interferon α-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
11. Chazouilleres O., Kim M., Combs C., Ferrell L., Bacchetti P., Roberts J., Ascher N., Neuwald P., Wilber J., Urdea M., Quan S., Sanchez-Pescador R., Wright T.L. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 106:1994;994-999.
12. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C. et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA. 9:1994;1294-1298.
13. Cooper, S., Erickson, A., Chein, D., Weiner, A., Houghton, M., Parham, P., Walker, C., 1998. CD8+ CTL directed against multiple hepatitis C viral proteins early in the course of infection correlate with immunity and endure following viral clearance. In: US-Japan Hepatitis Joint Panel Meeting. Pacific Grove, California, USA, 1998.
14. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1998;1493-1499.
15. Davis G.L., Lau J.Y.N. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26:1997;122S-127S.
16. de Man R.A., Bartholomeusz A.I., Niesters H.G.M., Zondervan P.E., Locarnini S.A. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29:1998;669-675.
17. Dickson R.C., Caldwell S.H., Ishitani M.B., Lau J.Y.N., Driscoll C.J., Stevenson W.C., McCullough C.S., Pruett T.L. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 61:1996;701-705.
18. Dienstag J.L., Feinstone S.M., Purcell R.H., Wong D.C., Alter H.J., Holland P.V. Non-A, non-B post-transfusion hepatitis. Lancet. 1:1977;560-562.
19. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1995;1657-1661.
20. Eckart M.R., Selby M., Masiarz F., Lee C., Berger K., Crawford K., Kuo C., Kuo G., Houghton M., Choo Q.L. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem. Biophys. Res. Commun. 192:1993;399-406.
21. Enomoto N., Sakamoto N., Kurosaki M., Marumo F., Sato C. The hypervariable region of the HCV genome changes sequentially during the progression of acute HCV infection to chronic hepatitis. J. Hepatol. 17:1993;415-416.
22. Erickson A.L., Houghton M., Choo Q.L., Weiner A.J., Ralston R., Muchmore E., Walker C.M. Hepatitis C virus-specific CTL responses in the liver of the chimpanzees with acute and chronic hepatitis C. J. Immunol. 151:1993;4189-4199.
23. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushalwar I.K. Lack of protective immunity against reinfection with HCV. Science. 258:1992;135-140.
24. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., Shapiro M., Purcell R.H. Prevention of HCV infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA. 91:1994;7792-7796.
25. Farci P., Mandas A., Coiana A., Lai M.E., Desmet V., Van Eyken P., Gibo Y., Caruso L., Scaecabarozzi S., Criscuolo D., Ryff J.C., Balestrieri A. Treatment of chronic hepatitis D with interferon-2a. N. Engl. J. Med. 330:1994;88-94.
26. Feinstone S.M., Kapikian A.Z., Purcell R.H., Alter H.J., Holland P.V. Transfusion associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292:1975;767-770.
27. Gane E.J., Naoumov N.V., Qian K., Mondelli M.U., Maertens G., Portmann B.C., Lau J.Y.N., Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 110:1996;167-177.
28. Ginsberg H.S., 1988. Pathogenesis of viral infections. In: Dulbecco, R., Ginsberg, H.S. (Eds.), Virology. JB Lippincott, Philadelphia, pp. 131-145.
29. Gish, R., Dickson, R.C., Self, P., The Lamivudine Transplant Group, 1997. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation. Hepatology 27, 260A.
30. González-Peralta R.P., Fang J.W.S., Davis G.L., Gish R., Lau G.K.K., Wu P.C., Lau J.Y.N. Hepatic response in chronic hepatitis C virus infection. Hepatology. 18:1993;24A.
31. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67:1993;2832-2843.
32. Heathcote J., Schalm S.W., Cianciara J., Farrell G., Feinmann V., Sherman M., Dhillon A.P., Moorat A.E., Gray D.F. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. J. Hepatol. 28:1998;43.
33. Hoofnagle J.H. Therapy of viral hepatitis. Digestion. 59:1998;563-578.
34. Innaimo S.F., Seifer M., Bisacchi G.S., Strandring D.N., Zahler R., Colonno R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1997;1444-1448.
35. Karayiannis P., McGarvey M.J. The GB hepatitis viruses. J. Vir. Hepat. 2:1995;221-226.
36. Khakoo S.I., Soni P.N., Savage K., Brown D., Dhiloon A.P., Poulter L.W., Dusheiko G.M. Lymphocyte and macrophage phenotypes in chronic hepatitis C. Am. J. Pathol. 150:1997;970.
37. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., Walker B.D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J. Immunol. 149:1992;3339-3344.
38. Koziel, M.J., 1998. The immunopathogenesis of hepatitis B virus infection. In: Schinazi, R.F., Sommadossi, J.P., Thomas H.C. (Eds.), Therapies for Viral Hepatitis. International Medical Press, London, pp. 54-64.
39. Lai C.L., Chien R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., Gray D.F. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:1998;61-68.
40. Lau J.Y.N., Krawczynski K., Negro F., González-Peralta R.P. In situ detection of hepatitis C virus: a critical appraisal. J. Hepatol. 24:1996;43-51.
41. Lechman M., Ihlenfeldt H.G., Braunschweiger I., Giers G., Jumg G., Matz B., Kaiser R., Sauerbach T., Spengler U. T and B cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C positive blood donors without viremia. Hepatology. 24:1996;790-795.
42. Leung N., Wu P.C., Tang S., Chan H.L.Y., Dent J., Roman L., Gray F. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine. Hepatology. 28:1998;1307A.
43. Linnen J., Wages J., Zhang-Keck Z.Y. et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 271:1996;505-508.
44. Lok A.S. Alpha-interferon therapy for chronic hepatitis B virus infection in children and Oriental patients. J. Gastroenterol. Hepatol. 6:1991;15-17.
45. Marcellin P., Lévy S., Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 26:1997;133S-136S.
46. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yersiz H., Goss J. A., Schmidt P., Pakrasi A., Artinian L., Murray N. G. B., Imagawa D. K., Holt C., Goldstein L. I., Stribling R., Busuttil R.W. Prophylaxis against hepatitis-B recurrence following liver-transplantation using combination lamivudine and hepatitis-B immune globulin. Hepatology. 28:1998;585-589.
47. McCutcheon M., Wehner N., Wensky A., Kushner M., Doan S., Hsiao L., Calabresi P., Ha T., Tran T.V., Tate K.M., Winkelhake J., Spack E.G. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods. 210:1997;149-166.
48. McHutchinson J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.L., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 329:1998;1485-1492.
49. Millich D.R., Jones J.E., Hughes J.L. et al. Is a function of the secreted hepatitis B antigen to induce immunologic tolerance? Proc. Nat. Acad. Sci. USA. 87:1990;6599-6603.
50. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:1996;706-714.
51. Missale G., Redeker A., Person J., Fowler P., Guilhot S., Schlicht H.J., Ferrari C., Chisari F.V. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J. Exp. Med. 177:1993;751-762.
52. Moradpour D., Kary P., Rice C.M., Blum H.E. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology. 28:1998;192-201.
53. Moradpour D., Wakita T., Wands J.R., Blum H.E. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochem. Biophys. Res. Commun. 246:1998;920-924.
54. Mosnier J.F., Degott C., Marcellin P., Hénin D., Erlinger S., Benhamou J.P. The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology. 17:1993;366-371.
55. Muller H.M., Pfaff E., Goesser T., Kallinowski B., Solbach C., Theilman L. Peripheral blood lymphocytes serve as a possible extrahepatic site for HCV replication. J. Gen. Virol. 74:1993;669-976.
56. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 24:1996;759-765.
57. Nelson D.R., Marousis C.G., Davis G.L., Rice C.M., Wong J.T., Houghton M., Lau J.Y.N. The role of hepatitis C virus-specific cytotoxic T-lymphocytes in chronic hepatitis VC. J. Immunol. 158:1997;1473-1481.
58. Nelson, D.R., Lau, J.YN., 1998. The pathogenesis of HCV infection. In: Schinazi, R.F., Sommadossi, J.P., Thomas, H.C. (Eds.), Therapies for Viral Hepatitis. International Medical Press, London, pp. 65-76.
59. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., Lau J.Y.N. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon α therapy in chronic hepatitis C. Hepatology. 28:1998;225-230.
60. Nery J.R., Weppler D., Rodriguez M., Ruiz P., Schiff E.R., Tzakis A.G. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation. 65:1998;1615-1621.
61. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 282:1998;103-107.
62. Nevens F., Main J., Honkoop P., Tyrrell D.L., Barber J., Sullivan M.T., Fevery J., De Man R.A., Thomas H.C. Lamivudine therapy for chronic HBV: a 6-month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
63. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 93:1996;4398-4402.
64. Onji M., Kikuchi Y., Kumon M., Masutomoto T., Ndano S., Kajino K., Horikee N., Ohta Y. Intrahepatic lymphocyte subpopulations and HLA class I expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology. 39:1992;340-343.
65. Perez V., Findor J., Tanno H., Sorda J. A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. Gut. 34(Suppl. 2):1993;S91-S94.
66. Perrillo, R.P., Schiff, E.R., Davis, G.L., Bodenheimer, H.C., Lindsay, K., Payne, J., Dienstag, J.L., O'Brien, C., Tamburro, C., Jacobson, I.M., The Hepatitis Interventional Therapy Group, 1990. A randomized, controlled trial of interferon α-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 323, 295-301.
67. Perrillo R.P. Interferon in the management of chronic hepatitis B. Dig. Dis. Sci. 38:1993;577-593.
68. Poynard T., Bedossa P., Chevallier M., Mathurin P., Lemonnier C., Trepo C., Couzigou P., Payen J.L., Sajus M., Costa J.M. A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N. Engl. J. Med. 332:1995;1457-1462.
69. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarkski J.P. Meta-analysis of interferon randomized trails in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
70. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomized trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis-C virus. Lancet. 352:1998;1426-1432.
71. Poynard T., McHutchinson J., Davis G.L., Estebanmur R., Goodman Z., Bedossa P., Albrecht J. Impact of interferon-α-2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis-C. Hepatology. 28:1998;1338A.
72. Reichard O., Norkrans G., Fryden A., Braconier J.H., Sonnerborg A., Weiland O. Randomized, double-blind, placebo-controlled trial of interferon-α-2b with and without ribavirin for chronic hepatitis-C. Lancet. 351:1998;83-87.
73. Rizzetto M., Hadziyannis S., Hansson B.G., Toukan A., Gust I. Hepatitis delta virus infection in the world; epidemiological patterns and clinical expression. Gastroenterol. Intern. 5:1992;18-32.
74. Rosina F., Cozzolongo R. Interferon in HDV infection. Antiviral. Res. 21:1994;357-368.
75. Rosina F., Pintus C., Meschievitz C., Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 13:1991;1052-1056.
76. Sakamoto N., Enomoto N., Kurosaki M., Marumo F., Sato C. Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection. J. Med. Virol. 42:1994;103-108.
77. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods. 210:1997;167-174.
78. Shimizu Y., Guidotti L.G., Fowler P., Chisari F.V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161:1998;4520-4529.
79. Shimizu Y.K., Iwamoto A., Hijikata M., Purcell R.H., Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc. Natl. Acad. Sci. USA. 89:1992;5477-5481.
80. Simons J.N., Leary T.P., Dawson G.J., Pilot-Matias T.J., Muerhoff A.S., Schlauder G.G., Desai S.M., Mushahwar I.K. Isolation of novel virus-like sequences associated with human hepatitis. Nat. Med. 1:1995;564-569.
81. Sobesky, C.R., Mathurin, P., Thevenot, T., Charlotte, F., Moussalli, J., Vidaud, M., Opolon, P., Poynard, T., 1998. Interferon-α reduces fibrosis progression independently of genotype, viral load and 3-month ALT response in chronic hepatitis C. Gastroenterology (in press).
82. Terrault N.A., Wright T.L., Roberts J.P., Ascher N.L. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver-transplant recipients. Hepatology. 28:1998;905A.
83. Terrault N.A., Zhou S., McCory R.W., Pruett T.L., Lake J.R., Roberts J.P., Ascher N.L., Wright T.L. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology. 28:1998;555-561.
84. Weiner A., Erickson A.L., Kansopon J., Crawford K., Muchmore E., Hughes A.L., Houghton M., Walker C.M. Persistent HCV infection in a chimpanzee is associated with the emergence of a cytotoxic T lymphocyte escape variant. Proc. Nat. Acad. Sci. USA. 92:1995;2755-2759.
85. Weiner A.J., Thaler M.M., Crawford K. et al. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J. Virol. 67:1993;4365.
86. Wu P.C., Lok A.S., Lau J.Y.N., Lauder I.J., Lai C.L. Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapy. Am. J. Clin. Pathol. 98:1992;402-407.
87. Yamagushi K., Tanaka E., Higashi K., Kiyosawa K., Matsumoto A., Furuta S., Hagesawa A., Tanaka S., Kohara M. Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis. Hepatology. 106:1994;1344-1348.
88. Yoshida E.M., Ma M.M., Davis J.E., Fischer K.P., Kneteman N.M., Erb S.R., Tyrrell D.L., Bain V.G. Post-liver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long term follow-up. Can. J. Gastro. 12:1998;125-129.
89. Zarski J.P., Causse X., Cohard M., Cougnard J., Trepo C. A randomized, controlled trial of interferon α-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. J. Hepatol. 20:1994;735-741.